Hypertension, Left Ventricular Dysfunction, Diabetic Nephropathies, Heart Failure
Aliskiren and valsartan are used to treat high blood pressure, which is when the force of blood against artery walls is too high. By lowering blood pressure, they help reduce the risk of heart disease, stroke, and kidney problems. Valsartan is also used to treat heart failure and improve survival after a heart attack. Both medicines aim to improve blood flow and reduce the heart's workload.
Aliskiren works by blocking renin, which is an enzyme that helps regulate blood pressure, reducing the production of angiotensin I. Valsartan blocks angiotensin II receptors, which relaxes blood vessels, allowing blood to flow more easily. Together, they provide a comprehensive approach to lowering blood pressure by targeting different points in the blood pressure regulation pathway.
The usual adult daily dose for aliskiren is 150 mg, which can be increased to 300 mg if needed. For valsartan, the common starting dose is 80 mg, adjustable up to 320 mg based on response. Both medicines are taken once daily, with or without food, but consistently in the same manner each day. Patients should follow their healthcare provider's instructions for dosage.
Common side effects of aliskiren include diarrhea and cough, while valsartan may cause dizziness and fatigue. Both medicines can lead to high potassium levels, known as hyperkalemia, and low blood pressure, called hypotension. Significant adverse effects shared by both include kidney problems and allergic reactions. Monitoring for these side effects is important, especially in patients with pre-existing conditions.
Aliskiren and valsartan should not be used during pregnancy due to the risk of fetal harm. They are contraindicated in patients with severe kidney impairment or a history of angioedema, which is swelling beneath the skin. Both can cause high potassium levels, so caution is advised in patients with kidney issues. Regular monitoring and communication with a healthcare provider are essential to manage these risks.
US(FDA)
NO
NO
Angiotensin 2 Receptor Blocker, Renin Inhibitor
NO